AP770A - Method for diagnosing schizophrenia. - Google Patents

Method for diagnosing schizophrenia. Download PDF

Info

Publication number: AP770A
Authority: AP; ARIPO
Prior art keywords: allele; schizophrenia; dna; primers; microsatellite
Prior art date: 1995-05-03

Application number

APAP/P/1997/001126A

Other languages

English (en)

Other versions

AP9701126A0 (en

Inventor

Claudine Laurent

Jacques Mallet

Rolando Meloni

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-03

Filing date

1996-04-29

Publication date

1999-10-06

1996-04-29 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1997-10-31 Publication of AP9701126A0 publication Critical patent/AP9701126A0/xx

1999-10-06 Application granted granted Critical

1999-10-06 Publication of AP770A publication Critical patent/AP770A/en

Links

238000000034 method Methods 0.000 title claims abstract description 46
201000000980 schizophrenia Diseases 0.000 title claims abstract description 38
108700028369 Alleles Proteins 0.000 claims abstract description 54
108091092878 Microsatellite Proteins 0.000 claims abstract description 34
238000000338 in vitro Methods 0.000 claims abstract description 3
238000001514 detection method Methods 0.000 claims abstract 3
108020004414 DNA Proteins 0.000 claims description 30
239000012634 fragment Substances 0.000 claims description 22
101150076211 TH gene Proteins 0.000 claims description 16
238000012163 sequencing technique Methods 0.000 claims description 13
238000000926 separation method Methods 0.000 claims description 8
101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 abstract description 2
BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical group ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 10
230000003321 amplification Effects 0.000 description 10
238000003199 nucleic acid amplification method Methods 0.000 description 10
230000000698 schizophrenic effect Effects 0.000 description 9
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
239000000523 sample Substances 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 7
210000004027 cell Anatomy 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
239000012139 lysis buffer Substances 0.000 description 5
230000007170 pathology Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
208000020016 psychiatric disease Diseases 0.000 description 5
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
238000013508 migration Methods 0.000 description 3
230000005012 migration Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
208000036752 Schizophrenia, paranoid type Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
150000003943 catecholamines Chemical class 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
208000002851 paranoid schizophrenia Diseases 0.000 description 2
230000037361 pathway Effects 0.000 description 2
150000008300 phosphoramidites Chemical class 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000011282 treatment Methods 0.000 description 2
239000008096 xylene Substances 0.000 description 2
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
208000001495 Disorganized Schizophrenia Diseases 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241001484259 Lacuna Species 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
101150034459 Parpbp gene Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
-1 acryl Chemical group 0.000 description 1
230000010386 affect regulation Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000003570 biosynthesizing effect Effects 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000013519 translation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000013598 vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

APAP/P/1997/001126A 1995-05-03 1996-04-29 Method for diagnosing schizophrenia. AP770A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9505264A FR2733766B1 (fr)	1995-05-03	1995-05-03	Methode de diagnostic de la schizophrenie
PCT/FR1996/000650 WO1996034980A1 (fr)	1995-05-03	1996-04-29	Methode de diagnostic de la schizophrenie

Publications (2)

Publication Number	Publication Date
AP9701126A0 AP9701126A0 (en)	1997-10-31
AP770A true AP770A (en)	1999-10-06

Family

ID=9478648

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1997/001126A AP770A (en)	1995-05-03	1996-04-29	Method for diagnosing schizophrenia.

Country Status (29)

Country	Link
US (1)	US6210879B1 (fr)
EP (1)	EP0826068B1 (fr)
JP (1)	JPH11504809A (fr)
KR (1)	KR19990008221A (fr)
CN (1)	CN1125881C (fr)
AP (1)	AP770A (fr)
AT (1)	ATE193559T1 (fr)
AU (1)	AU715264B2 (fr)
BG (1)	BG63017B1 (fr)
BR (1)	BR9608432A (fr)
CA (1)	CA2217332A1 (fr)
CZ (1)	CZ291234B6 (fr)
DE (1)	DE69608682T2 (fr)
DK (1)	DK0826068T3 (fr)
EA (1)	EA001037B1 (fr)
ES (1)	ES2148760T3 (fr)
FR (1)	FR2733766B1 (fr)
GR (1)	GR3033592T3 (fr)
HU (1)	HUP9802918A3 (fr)
NO (1)	NO974974L (fr)
NZ (1)	NZ308132A (fr)
OA (1)	OA10534A (fr)
PL (1)	PL183819B1 (fr)
PT (1)	PT826068E (fr)
RO (1)	RO116731B1 (fr)
SI (1)	SI0826068T1 (fr)
SK (1)	SK282119B6 (fr)
UA (1)	UA49827C2 (fr)
WO (1)	WO1996034980A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6566065B1 (en) *	1994-05-26	2003-05-20	Mcgill University	Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
WO1998023733A2 (fr) *	1996-11-27	1998-06-04	University Of Washington	Polymerases thermostables presentant une fidelite modifiee
AU2001288416A1 (en)	2000-08-24	2002-03-04	University Of Pittsburgh	Methods and systems for facilitating the diagnosis and treatment of schizophrenia
WO2002018548A2 (fr) *	2000-08-30	2002-03-07	Thomas Jefferson University	Elements de regulation de tyrosine hydroxylase 5' et utilisations de ceux-ci
US20070072233A1 (en) *	2001-05-01	2007-03-29	Levitt Pat R	Methods and systems for facilitating the diagnosis and treatment of schizophrenia
DE10141464A1 (de) *	2001-08-23	2004-03-04	Genprofile Ag I.Ins.	Sequenzvarianten des für neuropsychiatrische Krankheiten verantwortlichen Gens 22444 und deren Verwendung
US6764824B2 (en) *	2002-03-21	2004-07-20	Council Of Scientific And Industrial Research	Primers for screening schizophrenia and a method thereof
CN100342032C (zh) *	2003-05-19	2007-10-10	张岱	精神分裂症易感基因检测方法及易感基因和用途
US12162008B2 (en)	2008-09-23	2024-12-10	Bio-Rad Laboratories, Inc.	Partition-based method of analysis
US9417190B2 (en)	2008-09-23	2016-08-16	Bio-Rad Laboratories, Inc.	Calibrations and controls for droplet-based assays
US9399215B2 (en)	2012-04-13	2016-07-26	Bio-Rad Laboratories, Inc.	Sample holder with a well having a wicking promoter
US10512910B2 (en)	2008-09-23	2019-12-24	Bio-Rad Laboratories, Inc.	Droplet-based analysis method
US12090480B2 (en)	2008-09-23	2024-09-17	Bio-Rad Laboratories, Inc.	Partition-based method of analysis
US9764322B2 (en)	2008-09-23	2017-09-19	Bio-Rad Laboratories, Inc.	System for generating droplets with pressure monitoring
US9492797B2 (en)	2008-09-23	2016-11-15	Bio-Rad Laboratories, Inc.	System for detection of spaced droplets
EP4512526A3 (fr)	2008-09-23	2025-06-04	Bio-Rad Laboratories, Inc.	Système de dosage à base de gouttelettes
US8951939B2 (en)	2011-07-12	2015-02-10	Bio-Rad Laboratories, Inc.	Digital assays with multiplexed detection of two or more targets in the same optical channel
US9156010B2 (en)	2008-09-23	2015-10-13	Bio-Rad Laboratories, Inc.	Droplet-based assay system
US8709762B2 (en)	2010-03-02	2014-04-29	Bio-Rad Laboratories, Inc.	System for hot-start amplification via a multiple emulsion
US8633015B2 (en) *	2008-09-23	2014-01-21	Bio-Rad Laboratories, Inc.	Flow-based thermocycling system with thermoelectric cooler
US11130128B2 (en)	2008-09-23	2021-09-28	Bio-Rad Laboratories, Inc.	Detection method for a target nucleic acid
US8663920B2 (en)	2011-07-29	2014-03-04	Bio-Rad Laboratories, Inc.	Library characterization by digital assay
US9132394B2 (en)	2008-09-23	2015-09-15	Bio-Rad Laboratories, Inc.	System for detection of spaced droplets
WO2011120020A1 (fr)	2010-03-25	2011-09-29	Quantalife, Inc.	Système de transport de gouttelettes à des fins de détection
CA2767056C (fr) *	2009-09-02	2018-12-04	Bio-Rad Laboratories, Inc.	Systeme de melange de fluides par coalescence d'emulsions multiples
US8399198B2 (en)	2010-03-02	2013-03-19	Bio-Rad Laboratories, Inc.	Assays with droplets transformed into capsules
JP2013524169A (ja)	2010-03-25	2013-06-17	クァンタライフ・インコーポレーテッド	液滴によるアッセイ用の検出システム
CA2767182C (fr)	2010-03-25	2020-03-24	Bio-Rad Laboratories, Inc.	Generation de gouttelettes pour dosages sur gouttelettes
EP3574990B1 (fr)	2010-11-01	2022-04-06	Bio-Rad Laboratories, Inc.	Système de formation d'émulsions
US12097495B2 (en)	2011-02-18	2024-09-24	Bio-Rad Laboratories, Inc.	Methods and compositions for detecting genetic material
CN103534360A (zh)	2011-03-18	2014-01-22	伯乐生命医学产品有限公司	借助对信号的组合使用进行的多重数字分析
EP3395957B1 (fr)	2011-04-25	2020-08-12	Bio-Rad Laboratories, Inc.	Procédés et compositions d'analyse d'acide nucléique
CN107677831A (zh) *	2017-06-28	2018-02-09	深圳市龙岗中心医院	测定用于评估精神分裂症病人的诊断标志物的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994003640A1 (fr) *	1992-07-31	1994-02-17	Government Of The United States As Represented By Secretary Department Of Health And Human Services	Onze marqueurs d'adn polymorphes a repetition de microsatellites extremement instructifs

1995
- 1995-05-03 FR FR9505264A patent/FR2733766B1/fr not_active Expired - Lifetime
1996
- 1996-04-29 ES ES96914258T patent/ES2148760T3/es not_active Expired - Lifetime
- 1996-04-29 UA UA97105318A patent/UA49827C2/uk unknown
- 1996-04-29 NZ NZ308132A patent/NZ308132A/en unknown
- 1996-04-29 CN CN96193673A patent/CN1125881C/zh not_active Expired - Fee Related
- 1996-04-29 AT AT96914258T patent/ATE193559T1/de not_active IP Right Cessation
- 1996-04-29 HU HU9802918A patent/HUP9802918A3/hu unknown
- 1996-04-29 SI SI9630174T patent/SI0826068T1/xx unknown
- 1996-04-29 AU AU57678/96A patent/AU715264B2/en not_active Ceased
- 1996-04-29 US US08/930,117 patent/US6210879B1/en not_active Expired - Fee Related
- 1996-04-29 DK DK96914258T patent/DK0826068T3/da active
- 1996-04-29 BR BR9608432A patent/BR9608432A/pt not_active Application Discontinuation
- 1996-04-29 EP EP96914258A patent/EP0826068B1/fr not_active Expired - Lifetime
- 1996-04-29 AP APAP/P/1997/001126A patent/AP770A/en active
- 1996-04-29 RO RO97-02043A patent/RO116731B1/ro unknown
- 1996-04-29 CZ CZ19973467A patent/CZ291234B6/cs not_active IP Right Cessation
- 1996-04-29 EA EA199700355A patent/EA001037B1/ru not_active IP Right Cessation
- 1996-04-29 DE DE69608682T patent/DE69608682T2/de not_active Expired - Fee Related
- 1996-04-29 PT PT96914258T patent/PT826068E/pt unknown
- 1996-04-29 CA CA002217332A patent/CA2217332A1/fr not_active Abandoned
- 1996-04-29 KR KR1019970707747A patent/KR19990008221A/ko not_active Ceased
- 1996-04-29 WO PCT/FR1996/000650 patent/WO1996034980A1/fr not_active Ceased
- 1996-04-29 JP JP8533069A patent/JPH11504809A/ja not_active Ceased
- 1996-04-29 SK SK1479-97A patent/SK282119B6/sk unknown
1997
- 1997-10-28 NO NO974974A patent/NO974974L/no not_active Application Discontinuation
- 1997-11-03 PL PL96323178A patent/PL183819B1/pl not_active IP Right Cessation
- 1997-11-03 OA OA70124A patent/OA10534A/fr unknown
- 1997-11-03 BG BG102016A patent/BG63017B1/bg unknown
2000
- 2000-06-01 GR GR20000400502T patent/GR3033592T3/el not_active IP Right Cessation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994003640A1 (fr) *	1992-07-31	1994-02-17	Government Of The United States As Represented By Secretary Department Of Health And Human Services	Onze marqueurs d'adn polymorphes a repetition de microsatellites extremement instructifs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE LANCET, vol. 345, April 1995, page 932 XP002012401 MELONI, R. ET AL.: "Association of maniac-depressive illness with typrosine hydroxylase microsatellite marker" *

Also Published As

Publication number	Publication date
NO974974D0 (no)	1997-10-28
SK147997A3 (en)	1998-05-06
KR19990008221A (ko)	1999-01-25
SI0826068T1 (en)	2000-10-31
AU5767896A (en)	1996-11-21
OA10534A (fr)	2002-04-29
DK0826068T3 (da)	2000-08-28
CA2217332A1 (fr)	1996-11-07
AU715264B2 (en)	2000-01-20
EA001037B1 (ru)	2000-08-28
HUP9802918A2 (hu)	1999-03-29
PT826068E (pt)	2000-12-29
PL323178A1 (en)	1998-03-16
FR2733766B1 (fr)	1997-06-06
EP0826068A1 (fr)	1998-03-04
CZ346797A3 (cs)	1998-01-14
GR3033592T3 (en)	2000-09-29
EA199700355A1 (ru)	1998-08-27
CZ291234B6 (cs)	2003-01-15
NZ308132A (en)	1999-10-28
DE69608682T2 (de)	2000-10-26
PL183819B1 (pl)	2002-07-31
ATE193559T1 (de)	2000-06-15
JPH11504809A (ja)	1999-05-11
HUP9802918A3 (en)	2001-01-29
UA49827C2 (uk)	2002-10-15
RO116731B1 (ro)	2001-05-30
DE69608682D1 (de)	2000-07-06
CN1125881C (zh)	2003-10-29
WO1996034980A1 (fr)	1996-11-07
NO974974L (no)	1997-10-28
ES2148760T3 (es)	2000-10-16
BG102016A (en)	1998-11-30
AP9701126A0 (en)	1997-10-31
EP0826068B1 (fr)	2000-05-31
FR2733766A1 (fr)	1996-11-08
CN1183122A (zh)	1998-05-27
BR9608432A (pt)	1999-03-02
SK282119B6 (sk)	2001-11-06
BG63017B1 (bg)	2001-01-31
US6210879B1 (en)	2001-04-03

Publication	Publication Date	Title
AP770A (en)	1999-10-06	Method for diagnosing schizophrenia.
US7601521B2 (en)	2009-10-13	Detection of nucleic acid mutation associated with cancer by analysis of saliva
US5910407A (en)	1999-06-08	Method for detection of target nucleic acid by analysis of stool
EP1478781B1 (fr)	2010-04-14	Marqueurs microsatellites a repetitions mononucleotidiques permettant de detecter l'instabilite des microsatellites
US6083698A (en)	2000-07-04	Cancer susceptibility mutations of BRCA1
JP2002533054A (ja)	2002-10-08	Ｂｒｃａ２の癌罹患性突然変異
US6063567A (en)	2000-05-16	Method, reagents and kit for diagnosis and targeted screening for retinoblastoma
US6080544A (en)	2000-06-27	Methods for identifying nucleic acid mutations using mismatch modification
Brieger et al.	1999	Detection of a novel germline mutation in the von Hippel–Lindau tumour‐suppressor gene by fluorescence‐labelled base excision sequence scanning (F‐BESS)
WO1999015701A1 (fr)	1999-04-01	MUTATION DE SUSCEPTIBILITE 6495delGC DE BRCA2
MXPA97008251A (en)	1998-01-01	Method of detection of the gene associated with the schizofre
CN117925806A (zh)	2024-04-26	一种基于CRISPR/Cas13a的ABO血型基因型鉴定方法及所用组合物
Yang et al.	2000	• HLA-DQB1 Genotyping with Simple Automated DNA Sequencing and Single-Strand Conformation Polymorphism Analysis